Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

JB Chemicals and Pharmaceuticals Ltd

US Class III Ongoing · initiated 2025-09-12

Tablet/Capsules Imprinted with Wrong ID

Letco Medical LLC

US Class III Ongoing · initiated 2025-09-12

Labeling: Not Elsewhere Classified

Kids by Babyganics SPF 50 Mineral Sunscreen Totally Tropical (rollerball and continuous spray formulas)

Canada Type II Ongoing · initiated 2025-09-08

Product quality. Do not use the affected products. Consult a healthcare professional if you or your child has used a recalled product and there are health conce…

Sunforce Health & Organics products

Canada Type III Ongoing · initiated 2025-09-08

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

NazalActin Liquid

Canada Type III Ongoing · initiated 2025-09-08

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Sandoz Inc

US Class II Ongoing · initiated 2025-09-05

cGMP deviations: Temperature excursion during transportation.

Apotex Corp.

US Class II Ongoing · initiated 2025-09-05

Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns

Apotex Corp.

US Class II Ongoing · initiated 2025-09-05

Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns

Endo USA, Inc.

US Class III Ongoing · initiated 2025-09-05

Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-04

Failed Impurity/Degradation Specifications

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-04

Failed Impurity/Degradation Specifications

Skycare Compounding Laboratories Products

Canada Type III Ongoing · initiated 2025-09-04

Unauthorized product. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any heal…

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-09-03

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2025-09-03

Failed Dissolution Specifications-Out of Specification (OOS) observation for sulphate in Sodium Tartrate Dihydrate used for the production of Mertiatide.

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2025-09-03

Failed Impurities/Degradation Specifications

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories

US Class II Ongoing · initiated 2025-09-02

Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected…